US equities |
MU $1,035.84 ▼-4.79% NVDA $230.48 ▼-2.94% SNDK $1,609.46 ▼-4.90% AMD $620.68 ▼-3.90% INTC $107.08 ▼-5.34% AAPL $340.42 ▲+1.11% META $720.89 ▼-0.06% SPCX $160.57 ▼-4.19%
FinancialContent

Articles published by Mydecine Innovations Group Inc.

News headline image
Mydecine Innovations Group Receives Notice of Allowance from USPTO for its MYCO-005 Compound
From Mydecine Innovations Group Inc.
Via GlobeNewswire
Tickers CSE:MYCO MYCOF
News headline image
Mydecine Provides Q4 2023 Business Update
From Mydecine Innovations Group Inc.
Via GlobeNewswire
Tickers CSE:MYCO MYCOF
News headline image
Mydecine Innovations Group Announces Admission to Trading on the AQSE Growth Market in London, UK and First Day of Dealings
From Mydecine Innovations Group Inc.
Via GlobeNewswire
Tickers MYCOF
News headline image
Mydecine Announces Conditional Approval of CSE Listing
From Mydecine Innovations Group Inc.
Via GlobeNewswire
Tickers MYCOF
News headline image
Mydecine Innovations Group Files Prospectus Supplement, Announces Closing Under Share Subscription Agreement and Provides Update on Its Board of Directors
From Mydecine Innovations Group Inc.
Via GlobeNewswire
Tickers MYCOF
News headline image
Mydecine Reports its 2023 Annual General Shareholders' Meeting Results
From Mydecine Innovations Group Inc.
Via GlobeNewswire
Tickers MYCOF
News headline image
Mydecine Reports Positive Preclinical Results on the MYCO-006 Series of its Short-Acting MDMA Analogues
From Mydecine Innovations Group Inc.
Via GlobeNewswire
Tickers MYCOF
News headline image
Mydecine Innovations Group Provides Corporate Update
From Mydecine Innovations Group Inc.
Via GlobeNewswire
Tickers MYCOF
News headline image
Mydecine Reports Financial Results for the Year Ended December 2022
From Mydecine Innovations Group Inc.
Via GlobeNewswire
Tickers MYCOF
News headline image
Mydecine Innovations Group Closes Sale of Its Wholly-Owned Subsidiary, Mindleap Health Inc.
From Mydecine Innovations Group Inc.
Via GlobeNewswire
Tickers CSE:NARA MYCOF
News headline image
Mydecine Reports Financial Results for the Third Quarter of Fiscal Year 2022
From Mydecine Innovations Group Inc.
Via GlobeNewswire
Tickers MYCOF